Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Clinical utility of different lipid measures for prediction of coronary heart disease in men and women.

Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PW, D'Agostino RB, Vasan RS.

JAMA. 2007 Aug 15;298(7):776-85.

PMID:
17699011
2.
3.

Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease.

Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM.

Am J Cardiol. 2006 Nov 15;98(10):1363-8. Epub 2006 Sep 29.

PMID:
17134630
4.

Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy.

Jeyarajah EJ, Cromwell WC, Otvos JD.

Clin Lab Med. 2006 Dec;26(4):847-70. Review.

PMID:
17110242
5.

Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem.

Hayward RA, Hofer TP, Vijan S.

Ann Intern Med. 2006 Oct 3;145(7):520-30. Review.

PMID:
17015870
6.

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators.

Lancet. 2006 Sep 9;368(9539):919-28.

PMID:
16962881
7.

Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.

Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomfield HE, Robins SJ.

Circulation. 2006 Mar 28;113(12):1556-63. Epub 2006 Mar 13.

8.

Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.

Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, de Graaf J, Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Jungner I, Krauss RM, Kwiterovich P, Marcovina S, Packard CJ, Pearson TA, Reddy KS, Rosenson R, Sarrafzadegan N, Sniderman AD, Stalenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KM.

J Intern Med. 2006 Mar;259(3):247-58.

9.

Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study.

Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PW, D'Agostino RB, Vasan RS, Robins SJ.

Circulation. 2006 Jan 3;113(1):20-9. Epub 2005 Dec 27.

10.

Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B.

Stein EA, Sniderman A, Laskarzewski P.

Am J Cardiol. 2005 Nov 7;96(9A):36K-43K; discussion 34K-35K. Epub 2005 Sep 19. Review.

PMID:
16291013
11.

Reducing residual risk for patients on statin therapy: the potential role of combination therapy.

Davidson MH.

Am J Cardiol. 2005 Nov 7;96(9A):3K-13K; discussion 34K-35K. Epub 2005 Sep 12. Review.

PMID:
16291008
12.

Comparison of the relationships between serum apolipoprotein B and serum lipid distributions.

Kim BJ, Hwang ST, Sung KC, Kim BS, Kang JH, Lee MH, Park JR.

Clin Chem. 2005 Dec;51(12):2257-63. Epub 2005 Oct 7.

13.

Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study.

Festa A, Williams K, Hanley AJ, Otvos JD, Goff DC, Wagenknecht LE, Haffner SM.

Circulation. 2005 Jun 28;111(25):3465-72.

14.

Low-density lipoprotein particle number and risk for cardiovascular disease.

Cromwell WC, Otvos JD.

Curr Atheroscler Rep. 2004 Sep;6(5):381-7. Review.

PMID:
15296705
15.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association.

Circulation. 2004 Jul 13;110(2):227-39. Review. Erratum in: Circulation. 2004 Aug 10;110(6):763.

16.

Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study.

Freedman DS, Otvos JD, Jeyarajah EJ, Shalaurova I, Cupples LA, Parise H, D'Agostino RB, Wilson PW, Schaefer EJ.

Clin Chem. 2004 Jul;50(7):1189-200. Epub 2004 Apr 23.

17.
18.

The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.

Soedamah-Muthu SS, Colhoun HM, Thomason MJ, Betteridge DJ, Durrington PN, Hitman GA, Fuller JH, Julier K, Mackness MI, Neil HA; CARDS Investigators.

Atherosclerosis. 2003 Apr;167(2):243-55.

PMID:
12818407
19.

Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk.

Sniderman AD, St-Pierre AC, Cantin B, Dagenais GR, Despr├ęs JP, Lamarche B.

Am J Cardiol. 2003 May 15;91(10):1173-7.

PMID:
12745098
20.

Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment.

Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, Walldius G.

Lancet. 2003 Mar 1;361(9359):777-80. No abstract available.

PMID:
12620753
Items per page

Supplemental Content

Write to the Help Desk